Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039011 | 0.92 | POLB (0.55) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039017 | 0.91 | MEN1 (0.52) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039026 | 0.90 | HDAC6 (0.55) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039007 | 0.90 | RXFP1 (0.49) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17038962 | 0.90 | POLB (0.48) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17195576 | 0.87 | HDAC6 (0.58) | HDAC6HDAC1HDAC8HDAC2HDAC9 | |
| SCHEMBL17038748 | 0.86 | POLB (0.47) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039013 | 0.86 | RXFP1 (0.47) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039018 | 0.85 | MAPT (0.48) | POLBHDAC6HDAC1HDAC8HDAC2 | |
| SCHEMBL17039043 | 0.85 | FSCN1 (0.48) | POLBHDAC6HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3107902-B1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIV CORNELL CENTER FOR TECHNOLOGY ENTERPRISE & COMMERCIALIZATION CCTEC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY | 2020-11-12 | — | — | US | disclosed |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| WO-2019104067-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CORNELL UNIVERSITY (US) | 2019-05-31 | — | — | WO | disclosed |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2018-08-02 | — | — | US | disclosed |
| US-9850243-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2017-06-08 | — | — | US | disclosed |
| US-9573946-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY | 2015-10-22 | — | — | US | disclosed |
| WO-2015127125-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299191-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-10227345-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-20210340138-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | POLB 1691/4885HDAC6 86/4885HDAC1 382/4885 |
| US-20180215757-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-20200352911-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | POLB 1691/4885HDAC6 86/4885HDAC1 382/4885 |
| US-20170158692-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | POLB 1691/4885HDAC6 86/4885HDAC1 382/4885 |
| US-10941141-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
| US-20200039976-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | POLB 1358/4885HDAC6 76/4885HDAC1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.